[go: up one dir, main page]

KR880701735A - Bone induction composition - Google Patents

Bone induction composition

Info

Publication number
KR880701735A
KR880701735A KR1019880700231A KR880700231A KR880701735A KR 880701735 A KR880701735 A KR 880701735A KR 1019880700231 A KR1019880700231 A KR 1019880700231A KR 880700231 A KR880700231 A KR 880700231A KR 880701735 A KR880701735 A KR 880701735A
Authority
KR
South Korea
Prior art keywords
bmp
sequence
class
composition
culture medium
Prior art date
Application number
KR1019880700231A
Other languages
Korean (ko)
Other versions
KR970005583B1 (en
Inventor
엘리자베스 에이 왕
온 엠 워즈니
비키 에이 로센
Original Assignee
브루스 엠.에이슨
제네틱스 인스티튜트 인코포레이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/031,346 external-priority patent/US4877864A/en
Application filed by 브루스 엠.에이슨, 제네틱스 인스티튜트 인코포레이트 filed Critical 브루스 엠.에이슨
Priority claimed from PCT/US1987/001537 external-priority patent/WO1988000205A1/en
Publication of KR880701735A publication Critical patent/KR880701735A/en
Application granted granted Critical
Publication of KR970005583B1 publication Critical patent/KR970005583B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043—Mixtures of macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음No content

Description

골 유도 조성물Bone induction composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (20)

(a) BMP-1 ; (b) BMP-2 클래스Ⅰ ; (c) BMP-2 클래스Ⅱ ; (d) BMP-3 ; 및 그의 혼합물의 군에서 선택된 단백질을 약학적으로 수용 가능한 부형제와 함께 함유한 약학 조성물.(a) BMP-1; (b) BMP-2 class I; (c) BMP-2 class II; (d) BMP-3; And a pharmaceutical composition comprising a protein selected from the group of mixtures thereof with a pharmaceutically acceptable excipient. 제1항에 있어서, 단백질이 BMP-1인 조성물.The composition of claim 1, wherein the protein is BMP-1. 제1항에 있어서, 단백질이 BMP-2 클랜스 Ⅰ인 조성물.The composition of claim 1, wherein the protein is BMP-2 Clarence I. 제1항에 있어서, 단백질이 BMP-2 클래스 Ⅱ인 조성물.The composition of claim 1, wherein the protein is BMP-2 class II. 제1항에 있어서, 단백질이 BMP-3인 조성물.The composition of claim 1, wherein the protein is BMP-3. 제1항에 있어서, 뼈결함 부위에 조성물을 부여하고, 뼈형성 유도를 위한 구조를 제공할 수 있는 매트릭스를 더 함유하는 약학 조성물.The pharmaceutical composition of claim 1, further comprising a matrix capable of imparting the composition to the bone defect site and providing a structure for inducing bone formation. 제6항에 있어서, 매트릭스가 히드록시아파티트, 콜라겐, 폴리락트산 및 트리칼슘 포스페이트의 군에서 선택된 물질을 함유한 조성물.7. The composition of claim 6, wherein the matrix contains a substance selected from the group of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate. 유효량의 제1∼7항의 조성물질을 뼈형성이 필요한 환자에게 투여함을 특징으로 하는 뼈형성이 필요한 환자에서의 뼈형성 유도방법.A method for inducing bone formation in a patient in need of bone formation, comprising administering an effective amount of the composition of claim 1 to a patient in need of bone formation. 그를 위한 형질발현 조절서열과 연관 결합된 BMP-1을 코오딩하는 DNA 서열로 형질전환된 세포주를 적당한 배양 배지에서 배양하고, 이 배양지로부터 BMP-1을 분리함을 특징으로 하는 BMP-1의 제조방법.Preparation of BMP-1 characterized by culturing the cell line transformed with a DNA sequence encoding BMP-1 associated with the expression control sequence therefor in a suitable culture medium and separating BMP-1 from the culture medium. Way. 제9항에 있어서, DNA 서열이 실제로 표 Ⅵ의 뉴클레오티드 서열을 함유하는 방법.The method of claim 9, wherein the DNA sequence actually contains the nucleotide sequences of Table VI. 그를 위한 형질발현 조절서열과 연관 결합된 BMP-2 클래스 Ⅰ을 코오딩하는 DNA 서열로 형질전환된 세포주를 적당한 배양배지에서 배양하고, 이 배양배지로부터 BMP-2 클래스 Ⅰ을 분리함을 특징으로 하는 방법.A cell line transformed with a DNA sequence encoding BMP-2 class I associated with the expression control sequence therefor is cultured in a suitable culture medium, and the BMP-2 class I is separated from the culture medium. Way. 제11항에 있어서, DNA 서열이 실제로 표 Ⅶ의 뉴클레오티드 서열을 함유하는 방법.The method of claim 11, wherein the DNA sequence actually contains the nucleotide sequence of Table VII. 그를 위한 형질발현 조절서열과 연관결합된 BMP-2 클래스 Ⅱ를 코오딩하는 DNA 서열로 형질 전환된 세포주를 적당한 배양배지에서 배양하고, 이 배양배지로부터 BMP-2 클래스 Ⅱ를 분리함을 특징으로 하는BMP-2 클래스 Ⅱ의 제조방법.A cell line transformed with a DNA sequence encoding BMP-2 class II associated with the expression control sequence therefor is cultured in a suitable culture medium, and the BMP-2 class II is separated from the culture medium. Process for the preparation of BMP-2 Class II. 제13항에 있어서, DNA 서열이 실제로 표 Ⅷ의 뉴클레오티드 서열을 함유하는 방법.The method of claim 13, wherein the DNA sequence actually contains the nucleotide sequence of Table VII. 그를 위한 형질발현 조절서열과 연관 결합된 BMP-3을 코오딩하는 DNA 서열로 형질 전환된 세포주를 적당한 배양 배지에서 배양하고, 이 배양 배지로부터 BMP-3을 분리함을 특징으로 하는 BMP-3의 제조방법.A cell line transformed with a DNA sequence encoding BMP-3 associated with the expression control regulatory sequence therefor is cultured in a suitable culture medium, and the BMP-3 is separated from the culture medium. Manufacturing method. 제15항에 있어서, DNA 서열이 실제로 표 ⅣA 및 ⅣB의 뉴클레오티드 서열을 함유하는 방법.The method of claim 15, wherein the DNA sequence actually contains the nucleotide sequences of Tables IVA and IVB. 표 Ⅵ의 뉴클레오티드 서열 또는 엄격한 조건하에 이 서열에 혼성화하는 서열을 실제로 함유하며, 형질발현시 BMP-1의 실제적 특성을 나타내는 단백질을 코오딩하는, BMP-1 코오딩 cDNA서열.A BMP-1 encoding cDNA sequence which actually contains the nucleotide sequence of Table VI or a sequence which hybridizes to this sequence under stringent conditions and which encodes a protein exhibiting the actual properties of BMP-1 upon expression. 표 Ⅶ의 뉴클레오티드서열 또는 엄격한 조건하에 이 서열에 혼성화하는 서열을 실제로 함유하며, 형질발현시 BMP-2 클래스 Ⅰ의 실제적 특성을 나타내는 단백질을 코오딩하는, BMP-2 클래스 Ⅰ 코오딩 cDNA서열.A BMP-2 class I coding cDNA sequence which actually contains a nucleotide sequence of Table VII or a sequence which hybridizes to this sequence under stringent conditions and which encodes a protein exhibiting the actual properties of BMP-2 class I upon expression. 표 Ⅷ의 뉴클레오티드서열 또는 엄격한 조건하에 이 서열에 혼성화하는 서열을 실제로 함유하며, 형질발현시 BMP-2 클래스 Ⅱ의 실제적 특성을 나타내는 단백질을 코오딩하는, BMP-2 클래스 Ⅱ 코오딩 cDNA서열.A BMP-2 class II coding cDNA sequence which actually contains a nucleotide sequence of Table VII or a sequence which hybridizes to this sequence under stringent conditions and which encodes a protein exhibiting the actual properties of BMP-2 class II upon expression. 표 ⅣA 및 ⅣA의 뉴클레오티드 서열 또는 엄격한 조건하에 이 서열에 혼성화하는 서열을 실제로 함유하며, 형질발현시 BMP-3의 실제적 특성을 나타내는 단백질을 코오딩하는, BMP-3 코오딩 cDNA서열.The BMP-3 encoding cDNA sequence, which actually contains the nucleotide sequences of Tables IVA and IVA or sequences that hybridize to these sequences under stringent conditions and which encodes a protein exhibiting the actual properties of BMP-3 upon expression. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880700231A 1986-07-01 1987-06-30 Novel osteoinductive compositions KR970005583B1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US88077686A 1986-07-01 1986-07-01
US880,776 1986-07-01
US94377686A 1986-12-17 1986-12-17
US943,332 1986-12-17
US943,776 1986-12-17
US2828587A 1987-03-20 1987-03-20
US028,285 1987-03-20
US031,346 1987-03-26
US07/031,346 US4877864A (en) 1987-03-26 1987-03-26 Osteoinductive factors
PCT/US1987/001537 WO1988000205A1 (en) 1986-07-01 1987-06-30 Novel osteoinductive compositions

Publications (2)

Publication Number Publication Date
KR880701735A true KR880701735A (en) 1988-11-04
KR970005583B1 KR970005583B1 (en) 1997-04-18

Family

ID=68233430

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880700231A KR970005583B1 (en) 1986-07-01 1987-06-30 Novel osteoinductive compositions

Country Status (1)

Country Link
KR (1) KR970005583B1 (en)

Also Published As

Publication number Publication date
KR970005583B1 (en) 1997-04-18

Similar Documents

Publication Publication Date Title
KR920700291A (en) Bone induction composition
Schmid et al. A short chain (pro) collagen from aged endochondral chondrocytes. Biochemical characterization.
Steinert et al. Complete amino acid sequence of a mouse epidermal keratin subunit and implications for the structure of intermediate filaments
KR900700617A (en) Bone and Cartilage Inducing Compositions
KR880701288A (en) Preparation of M-CSF
Aliapoulios et al. Thyrocalcitonin inhibition of bone resorption induced by parathyroid hormone in tissue culture
US5661008A (en) Recombinant human factor VIII derivatives
BR9712348A (en) isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue.
KR960706559A (en) BMP-12, BMP-13 and dry-derived compositions thereof (BMP-12, BMP-13 ANDTENDON-INDUCING COMPOSITIONS THEREOF)
KR970700438A (en) MACROPHAGE INFLAMMATORY PROTEINS -3, -4 AND -1sg (g)
KR960701997A (en) BMP-10 composition [BMP-10 COMPOSITIONS]
KR950700331A (en) DNA sequences encoding novel growth / differentiation factors (DNA SEQUENCES ENCODING NOVEL GROWTH / DIFFERENTIATION FACTORS)
IL117175A0 (en) Proteins and their production
BR9205640A (en) Apolipoprotein dimer ai-milano, pharmacological composition, process of preparation of the dimer, use of this in the preparation of medicines and process for the treatment of atherosclerosis and cardiovascular diseases
ATE325131T1 (en) NEW PROTEIN AND METHOD FOR THE PRODUCTION THEREOF
KR927002375A (en) Megakaryocyte forming factor
PT93910A (en) A product for the preparation of a blood protein by means of a blood cell
FR2619314B1 (en) FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US5200395A (en) Pharmaceutical composition of BUF-5 for treating anemia
PT86558B (en) PROCESS FOR THE PREPARATION OF BASIC FIBROBLAST DEVELOPMENT FACTORS
KR930010177A (en) Hybrid Transformation Growth Factor
KR890701731A (en) Method of manufacturing kallikrein
ATE88500T1 (en) DNA SEQUENCES CODING FOR PROTEINS WITH THE BIOLOGICAL ACTIVITY OF THE HUSI-TYPE INHIBITORS, GENETIC METHODS FOR THE PRODUCTION OF THESE PROTEINS, AND PHARMACEUTICALS CONTAINING THESE PROTEINS.
Postlethwaite et al. Identification of a chemotactic epitope in human transforming growth factor‐β1 spanning amino acid residues 368–374
KR880701735A (en) Bone induction composition

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19880229

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920624

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19880229

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19960202

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19961202

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970319

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970718

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19971010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19971010

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000223

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010928

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20021002

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20030930

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20040930

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20050930

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20060929

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20060929

Start annual number: 10

End annual number: 10

EXPY Expiration of term
PC1801 Expiration of term